18 Eylül 2024 Çarşamba
Giresun University academicians continue to contribute to humanity with their research. In this context, the list of the world's most influential scientists, prepared annually in cooperation with Stanford University and the Netherlands-based scientific publishing company Elsevier, was published in two separate categories as ‘Annual Impact’ and ‘Career-Long Impact’. A total of 1518 academics from Turkey managed to enter the Annual Impact list, while a total of 1171 academics from Turkey managed to enter the Career Long Impact list.
While Prof. Dr. İmdat İşcan and Prof. Dr. Erol Eğrioğlu from the Faculty of Arts and Sciences of our University were included in the ‘Career Long Impact’ list, where the world's most influential scientists are ranked every year by Stanford University, Assoc. Prof. Dr. Fikret Ustaoğlu, Prof. Dr. İmdat İŞCAN, Prof. Dr. Yalçın Tepe, Prof. Dr. Erol Eğrioğlu and Prof. Dr. Eren Baş from the Faculty of Arts and Sciences of our University, and Assoc. Dr. Salih Durdu from the Faculty of Engineering were included in the ‘Annual Impact’ list.
Prof. Dr. İmdat İşcan from the Faculty of Arts and Sciences of our University was ranked 198.016 in the ‘Career Long Impact’ list, while his ranking among academics in Turkey was 570. Prof. Dr. Erol Eğrioğlu's ranking was 200,586, while his ranking among academicians in Turkey was 645.
In the field of Artificial Intelligence and Image Processing, 99 academicians from Turkey entered the Career Long Impact list, while Prof. Dr. Erol Eğrioğlu's ranking was 51. The world ranking of Prof. Dr. Erol Eğrioğlu in the field of Artificial Intelligence and Image Processing was 4753 out of 399,064 academicians.
In the annual impact list, Assoc. Prof. Dr. Fikret Ustaoğlu's world ranking was 32,951, while Prof. Dr. İmdat İŞCAN's ranking was 43,976, Prof. Dr. Yalçın Tepe's ranking was 65,467, Prof. Dr. Erol Eğrioğlu's ranking was 124,678, Assoc. Dr. Salih Durdu's ranking was 188,591 and Prof. Dr. Eren Baş's ranking was 316,960.
We wish our esteemed academicians continued success.